Form 4 for BMRN BIOMARIN PHARMACEUTICAL INC
Accepted 2023-04-12 00:00:00 ET · period of report 2023-04-10 · accession 0001209191-23-024073 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-04-12 | 2023-04-10 | BMRN | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale+OE | $99.56 | -10.0K | 425.9K | -2% | -$995.6K |
| D | 2023-04-12 | 2023-04-10 | BMRN | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $67.81 | +10.0K | 435.9K | +2% | +$678.1K |
| D | 2023-04-12 | 2023-04-10 | BMRN | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $0.00 | -10.0K | 129.1K | -7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-10 | S | D | 10,000 | $99.56 | 425,896 | D | — | — | (F1) Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. |
| 2 | Common | Common Stock | 2023-04-10 | M | A | 10,000 | $67.81 | 435,896 | D | — | — | (F1) Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. |
| 3 | Derivative | Stock Option (Right to Buy Common Stock) | 2023-04-10 | M | D | 10,000 | $0.00 | 129,130 | D | $67.81 · 2013-11-15 to 2023-05-14 | 10,000 Common Stock | (F1) Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. (F2) Reflects the number of options outstanding after the transactions from this specific stock option grant. |